Lumpectomy and breast irradiation for breast cancer after radiotherapy for lymphoma.
Six women received irradiation for lymphoma (Hodgkin's disease, n = 5; non-Hodgkin's disease, n = 1) to at least a mediastinal field (n = 2) or to a mantle field (n = 4), and subsequently developed breast cancer 10-27 years later. Three patients also received chemotherapy as a component of therapy for lymphoma. For breast cancer, all were treated with lumpectomy and breast irradiation to 5,000 cGy in 25 fractions plus a 1,000 cGy/5 fraction boost to the operative area using electrons. Two patients received adjuvant chemotherapy and three others tamoxifen for breast cancer. All women are alive and free of disease 15-118 months (median, 60 months) following breast irradiation. There have been no cases of significant acute reactions and no late sequelae such as skin pigmentation changes subcutaneous fibrosis, rib fractures, cardiac disease, or pulmonary fibrosis. The cosmetic result is considered good or excellent in all. Lumpectomy and breast irradiation is not contraindicated in the woman who develops breast cancer many years after irradiation of lymph node regions above the diaphragm for lymphoma.
Karasek
K
K
Department of Radiation Oncology, University of Pittsburgh Medical Center, Pennsylvania 15213, USA.
Deutsch
M
M
D000328:Adult; D001943:Breast Neoplasms / Q000209:etiology / Q000532:radiotherapy* / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000209:etiology / Q000532:radiotherapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000532:radiotherapy*; D015412:Mastectomy, Segmental; D008479:Mediastinal Neoplasms / Q000532:radiotherapy; D009381:Neoplasms, Radiation-Induced / Q000209:etiology / Q000532:radiotherapy* / Q000601:surgery*; D016609:Neoplasms, Second Primary / Q000532:radiotherapy* / Q000601:surgery*; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage